In the second quarter of 2023, we advanced our business, as the operating environment continued to slowly improve from the post-pandemic challenges. Our team has been working diligently to maximize the potential of our commercial brands, progress our pipeline and pursue select acquisitions. 

We’re pleased to share several notable developments from an overall successful quarter: 

The results of the study were published in the journal Pediatric Drugs and support the recent FDA approval of Caldolor® in infants 3 to 6 months of age. Caldolor® is the only non-opioid injectable product approved to treat pain and fever in infants. 

Thank you to our Cumberland team for their continued support and hard work during this quarter and first half of the year. We are pleased with the developments in the second quarter and look forward to sharing more updates throughout the remainder of the year. 

Leave a Reply

Your email address will not be published. Required fields are marked *